Developments Lexeo reports positive data from study of LX2020 in PKP2-ACM Lexeo Therapeutics (NASDAQ: LXEO) has announced positive interim data from the ongoing HEROIC-PKP2 Phase 1/2 clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). According to... November 16, 2026